To include your compound in the COVID-19 Resource Center, submit it here.

Nektar gains on updated response data for NKTR-214

Nektar Therapeutics (NASDAQ:NKTR) added $18.32 (22%) to $102.87 on Friday after President and CEO Howard Robin said that two additional renal cell carcinoma (RCC) patients who previously achieved stable disease have converted to responders

Read the full 346 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE